Eun-Kyung Cho
Oncology Eun-Kyung Cho Favorite Doctor
  • SpecialtyOncology
  • Site Blog
Appointment
Schedule
의료진 진료일정
Week M T W T F S
AM   Present Present      
PM       Present    
Clinical Interests

Lung cancer
Breast cancer
Head and neck cancer
Thyroid cancer

Education
Education
1996.02 Hanyang University College of Medicine, Ph.D.
1992.08 Hanyang University College of Medicine, M.S.
1988.02 Hanyang University College of Medicine, M.D.
Career
Career
2011.04~ Gachon University Gil Medical Center, Professor
2009.09~2017.03 Head of Department Hematology Oncology, Gachon University Gil Medical Center
2005.05~2007.02 Harvard Medical School Brigham and Women's Hospital
2005.03~2011.03 Gachon University Gil Medical Center, Associate Professor
2001.03~2005.02 Gachon University Gil Medical Center, Assistant Professor
1999.03~2001.02 Gachon University Gil Medical Center, Full-time Instructor
1996.03~1997.02 Seoul National University College of Medicine, Cancer Research Center, Senior Researcher
1995.03~1996.02 Seoul National University Hospital, Full-time Doctor
1988.03~1995.02 National Medical Center, Intern
More
Community
Community
More
Training
Training
2005.05~2007.02 Harvard Medical School, Brigham and Women's Hospital
License
License
1988 License of Medical Doctor
1995 Internal Medicine, Specialist
1997 Hematology oncology, Specialist
Eun-Kyung Cho
Paper
Paper
2020 Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.J Thorac Oncol. 2020 Jan;15(1):80-90
2020 FLAURA Investigators. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
2019 Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019 Dec;20(12):1681-1690
2019 Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing. PLoS One. 2019 Nov 25;14(11):e0224379
2019 Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Nov 15;25(22):6644-6652
2019 Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer. 2019 Sep;135:66-72.
2019 Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset. J Thorac Oncol. 2019 Jan;14(1):99-106
2019 A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. Cancer Res Treat. 2019 Apr;51(2):718-72
2018 CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer J Clin Oncol. 2018 Aug 28:
2018 Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. Lung Cancer. 2018 Aug;122:234-242
2018 FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. . 2018 Jan 11;378(2):113-125.
2018 Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med. 2018 Jan;33(1):168-175
2018 Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). J Pathol Transl Med. 2018 May;52(3):148-156
2018 Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.. Clin Lung Cancer. 2018 May;19(3):270-279
2017 CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. Ann Oncol. 2017 Nov 1;28(suppl_10).
2017 Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017 Nov 10;35(32):3662-3670
2017 Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol. 2017 Aug 10;35(23):2613-2618
2017 Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer. Eur J Cancer Care (Engl). 2018 Jan;27(1).
2017 Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Cancer Res Treat. 2017 Apr;49(2):423-429
2017 Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin In East Asian Patients with Stage IV Squamous Non-Small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. Cancer Res Treat. 2017 Oct;49(4):937-946.
2017 . Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Support Care Cancer. 2017 Mar;25(3):801-809
2017 An Open-label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer. Cancer Res Treat. 2017 Jul;49(3):569-577
2017 Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 18. doi: 10.1056/NEJMoa1713137. [Epub ahead of print]
2017 Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017 Nov 10;35(32):3662-3670. doi: 10.1200/JCO.2017.72.7297. Epub 2017 Sep 13.
2017 Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, Cho BC. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol. 2017 Aug 10;35(23):2613-2618. doi: 10.1200/JCO.2016.71.3701. Epub 2017 May 18.
2017 Park YH, Kim TY, Im YH, Lee KS, Park IH, Sohn J, Lee SH, Im SA, Kim JH, Kim SH, Lee SJ, Koh SJ, Lee KH, Choi YJ, Cho EK, Lee S, Kang SY, Seo JH, Kim SB, Jung KH. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Cancer Res Treat. 2017 Apr;49(2):423-429. doi: 10.4143/crt.2016.191. Epub 2016 Aug 3.
2017 Park K, Cho EK, Bello M, Ahn MJ, Thongprasert S, Song EK, Soldatenkova V, Depenbrock H, Puri T, Orlando M. Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin In East Asian Patients with Stage IV Squamous Non-Small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. Cancer Res Treat. 2017 Oct;49(4):937-946. doi: 10.4143/crt.2016.423. Epub 2017 Jan 6.
2017 Mok TS1, Wu Y-L1, Ahn M-J1, Garassino MC1, Kim HR1, Ramalingam SS1, Shepherd FA1, He Y1, Akamatsu H1, Theelen WS1, Lee CK1, Sebastian M1, Templeton A1, Mann H1, Marotti M1, Ghiorghiu S1, Papadimitrakopoulou VA1; AURA3 Investigators. Collaborators ; Cho EK, Min YJ, Lee KH, Choi J-H, Lee G-W, Lee SS, Kim J-S, Felip Font E, Isla Casado D, Corral Jaime J, Ponce Aix S, Garrido López P, Cobo Dols M, Öhman R, Bergman B, Kölbeck K-G, Yang C-H, Su W-C, Hsia T-C, Tsai C-M, Chang G-C, Yang C-T, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
2017 Kim JE, Jang JS, Kim JW, Sung YL, Cho CH, Lee MA, Kim DJ, Ahn MJ, Lee KY, Sym SJ, Lim MC, Jung H, Cho EK, Min KW. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. Support Care Cancer. 2017 Mar;25(3):801-809. doi: 10.1007/s00520-016-3463-0. Erratum in: Support Care Cancer. 2017 Feb 14;:. . Support Care Cancer. 2017 May;25(5):1741.
2017 Park IH1, Sohn JH2, Kim SB3, Lee KS1, Chung JS4, Lee SH2, Kim TY5, Jung KH3, Cho EK6, Kim YS7, Song HS8, Seo JH9, Ryoo HM10, Lee SA11, Yoon SY12, Kim CS13, Kim YT14, Kim SY15, Jin MR16, Ro J1. An Open-label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer. Cancer Res Treat.2017 Jul;49(3):569-577. doi: 10.4143/crt.2016.289. Epub 2016 Sep 12.
2017 Kim EY, Lee HY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM, Kim JH. Prognostic significance of cachexia score assessed by CT in male patients with small cell lung cancer. Eur J Cancer Care (Engl). 2017 Apr 20. doi: 10.1111/ecc.12695. [Epub ahead of print]
2016 Hong J, Lee S, Chun G, Jung JY, Park J, Ahn JY, Cho EK, Shin DB, Lee JH. Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma. Blood Res. 2016 Jun;51(2):113-21. doi: 10.5045/br.2016.51.2.113. Epub 2016 Jun 23.
2016 Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904.
2016 Park K, Lee JS, Han JY, Lee KH, Kim JH, Cho EK, Cho JY, Min YJ, Kim JS, Kim DW. 1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose. J Thorac Oncol. 2016 Apr;11(4 Suppl):S113. doi: 10.1016/S1556-0864(16)30243-X. Epub 2016 Apr 15.
2016 Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med. 2016 Apr 20. doi: 10.3904/kjim.2015.158. [Epub ahead of print] (corresponding author)
2016 Kim YS1, Cho EK1, Woo HS1, Hong J1, Ahn HK1, Park I1, Sym SJ1, Kyung SY2, Kang SM2, Park JW2, Jeong SH2, Park J1, Lee JH1, Shin DB1. Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer. Cancer Res Treat. Cancer Res Treat. 2016 Jan;48(1):80-7. doi: 10.4143/crt.2014.307. (corresponding author )
2016 Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Prognostic Factors for Risk Stratification of Patients Recurrent or Metastatic Pancreatic Adenocarcinoma Who were Treated with Gemcitabine-Based Chemotherapy. Cancer Res Treat. 2016 Oct;48(4):1264-1273.
2016 Park K, Kim JH, Cho EK, Kang JH, Shih JY, Zimmermann AH, Lee P, Alexandris E, Puri T, Orlando M. East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small-Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy (REVEL). 2016 Oct;48(4):1177-1186. Epub 2016 Feb 22.
2016 Ahn HK, Hwang IC, Lee JS, Sym SJ, Cho EK, Shin DB. Neutrophil-Lymphocyte Ratio Predicts Survival in Terminal Cancer Patients. J Palliat Med. 2016 Apr;19(4):437-41. doi: 10.1089/jpm.2015.0277. Epub 2016 Feb 17.
2016 Lee MA, Cho EK, Oh SY, Ahn JB, Lee JY, Thomas B, Jung H, Kim JG. Clinical Practices and Outcomes on CINV Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian ChemoTherapy InduCed Emesis burden of illness Study. Cancer Res Treat. 2016 Oct;48(4):1420-1428.
2016 Lee JY, Qing X, Xiumin W, Yali B, Chi S, Bak SH, Lee HY, Sun JM, Lee SH, Ahn JS, Cho EK, Kim DW, Kim HR, Min YJ, Jung SH, Park K, Mao M, Ahn MJ. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874.
2016 Kang JH, Ahn MJ, Kim DW, Cho EK, Kim JH, Shin SW, Wang X, Kim JS, Orlando M, Park K. Tolerability and Outcomes of First-line Pemetrexed+Cisplatin Followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial. Cancer Res Treat. 2016 Apr;48(2):458-64. doi: 10.4143/crt.2015.135. Epub 2015 Oct 14.
2016 Lee KH, Kim JY, Lee MH, Han HS, Lim JH, Park KU, Park IH, Cho EK, Yoon SY, Kim JH, Choi IS, Park JH, Choi YJ, Kim HJ, Jung KH, Kim SY, Oh DY, Im SA. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. Support Care Cancer2016 Apr;24(4):1709-17. doi: 10.1007/s00520-015-2963-7. Epub 2015 Oct 1.
2016 Cho EK. Treatment of Advanced and metastatic squamous Non-small Cell Lung Cancer. Korean J of Medicine. 2016;90(1):1-6. (in Korean)
2016 Kim EY, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM, Kim JH. Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CT. Support Care Cancer. 2016 Nov;24(11):4721-6. doi: 10.1007/s00520-016-3321-0. Epub 2016 Jun 30.
2016 Kim YS, Kim EY, Ahn HK, Cho EK, Jeong YM, Kim JH. Prognostic significance of CT-emphysema score in patients with advanced squamous cell lung cancer. J Thorac Dis. 2016 Aug;8(8):1966-73. doi: 10.21037/jtd.2016.06.70.
2015 Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, Tsai CM, Kim JH, Cho EK, Hoffman PC, Orlov SV, Serwatowski P, Wang J, Foley MA, Horan JD, Shepherd FA. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2015 Dec 1;33(34):4007-14. doi: 10.1200/JCO.2015.61.8918. Epub 2015 Aug 31.
2015 Park S, Hong J, Hwang I, Ahn JY, Cho EY, Park J, Cho EK, Shin DB, Lee JH. Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy J Geriatr Oncol. 2015 Nov;6(6):470-8. doi: 10.1016/j.jgo.2015.10.183. Epub 2015 Oct 27.
2015 Kim YS, Sym SJ, Baek MY, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB. Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study. Cancer Chemother Pharmacol. 2015 Dec;76(6):1267-72. doi: 10.1007/s00280-015-2881-x. Epub 2015 Oct 19.
2015 Kim EY1, Kim YS, Park I, Ahn HK, Cho EK, Jeong YM. Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer. J Thorac Oncol. 2015 Dec;10(12):1795-9.
2015 Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, Kim SR, Lee KH, Song HS, Choi YL, Sun JM, Jung SH, Ahn MJ, Park K. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6.
2015 Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD; LUX-Lung 8 Investigators. ;Soria JC, Goss G, Ardizzoni A, Felip E, Gadgeel S, Georgoulias V, Lu S, Chand V, Fein L, Martin C, Pilnik N, Richardet E, Burghuber O, Eisterer W, Flicker M, Cho EK, Guclu S, Kiyik M, Sevinc A, Barton R, Boleti E, Chan S, Popat S, Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.
2015 Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Briggs P, Broad A, Clingan P, Hui R, Leong D, Aigner K, Pirker R, Ulsperger E, Bolitschek J, Bosquee L, Bustin F, Sobrero A, Tiseo M, Zilembo N, Cho EK, Kim HK, Kim JH, Kim SW, Lee JS, Park K, Song EK, Yhim HY, Bello M 3rd, Fajardo TN, Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1.
2015 Hong J, Woo HS, Ahn HK, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia. Support Care Cancer. 2015 May 19. [Epub ahead of print]
2015 Baek JH, Sun JM, Min YJ, Cho EK, Cho BC, Kim JH, Ahn MJ, Park K. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. Lung Cancer. 2015 Feb;87(2):148-54. doi: 10.1016/j.lungcan.2014.11.013. Epub 2014 Nov 29.
2014 Cho EK, Park JY, Lee KH, Song HS, Min YJ, Kim YH, Kang JH. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer. Cancer Chemother Pharmacol. 2014 Jan;73(1):9-16. doi: 10.1007/s00280-013-2264-0. Epub 2013 Dec 12.
2014 Ahn HK, Jung M, Sym SJ, Shin DB, Kang SM, Kyung SY, Park JW, Jeong SH, Cho EK. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Aug;74(2):277-82. doi: 10.1007/s00280-014-2498-5. Epub 2014 Jun 7.(corresponding author )
2014 Ahn HK, Jung M, Ha SY, Lee JI, Park I, Kim YS, Hong J, Sym SJ, Park J, Shin DB, Lee JH, Cho EK. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. Tumour Biol. 2014 Jun;35(6):5735-40. doi: 10.1007/s13277-014-1760-0. Epub 2014 Apr 16.(corresponding author )
2014 Woo HS, Ahn HK, Lee HY, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK. Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Invest New Drugs. 2014 Dec;32(6):1311-5. doi: 10.1007/s10637-014-0146-x. 2014 Aug 23. [Epub ahead of print]. (corresponding author )
2014 Hong J, Woo HS, Kim H, Ahn HK, Sym SJ, Park J, Ahn JY, Cho EK, Shin DB, Lee JH. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Cancer Sci. 2014 Dec;105(12):1569-75. doi: 10.1111/cas.12544. Epub 2014 Nov 5.
2014 Kim J, Hong J, Kim SG, Hwang KH, Kim M, Ahn HK, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Prognostic Value of Metabolic Tumor Volume Estimated by (18)F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease. Nucl Med Mol Imaging. 2014 Sep;48(3):187-95. doi: 10.1007/s13139-014-0280-6. Epub 2014 May 29.
2014 Kim YS, Kim EY, Park HK, Ahn HK, Hong J, Cho EK, Choi HY. Intensive Postoperative Surveillance using Chest CT and Bone Scan in Patients with Locally Advanced Breast Cancer. Breast J. 2014 Sep-Oct;20(5):558-9. doi: 10.1111/tbj.12326. Epub 2014 Jul 17.
2014 Kim YS, Sym SJ, Park SH, Park I, Hong J, Ahn HK, Park J, Cho EK, Lee WK, Chung M, Lee JH, Shin DB. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. Cancer Chemother Pharmacol. 2014 Jan;73(1):163-9. doi: 10.1007/s00280-013-2334-3. Epub 2013 Nov 8.
2014 Hong J, Kim JH, Lee KH, Ahn HK, Park S, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Oct;55(10):2312-8. doi: 10.3109/10428194.2014.882505. Epub 2014 Mar 7.
2013 Ahn JS, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer. 2013 Dec;82(3):455-60.
2013 Kim YK, Sung YM, Hwang KH, Cho EK, Choi HY. Pseudopathologic vertebral body enhancement in the presence of superior vena cava obstruction on computed tomography.Spine J. 2013 Oct 7. pii: S1529-9430(13)01361-2. doi: 10.1016/j.spinee.2013.07.440.
2013 Hong J, Yoon HH, Ahn HK, Sym SJ, Park J, Park PW, Ahn JY, Park S, Cho EK, Shin DB, Lee JH. Prognostic role of serum lactate dehydrogenase beyond initial diagnosis: a retrospective analysis of patients with diffuse large B cell lymphoma. Acta Haematol. 2013;130(4):305-11. doi: 10.1159/000353127. Epub 2013 Aug 31.
2013 Ahn SJ, Kim YS, Kim EY, Park HK, Cho EK, Kim YK, Sung YM, Choi HY. The value of chest CT for prediction of breast tumor size: comparison with pathology measurement. World J Surg Oncol. 2013 Jun 6;11:130. doi: 10.1186/1477-7819-11-130.
2013 Sym SJ, Hong J, Park J, Cho EK, Lee JH, Park YH, Lee WK, Chung M, Kim HS, Park SH, Shin DB. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol.
2013 Hong J, Moon SM, Ahn HK, Sym SJ, Park YS, Park J, Cho YK, Cho EK, Shin DB, Lee JH. Comparison of characteristics of bacterial bloodstream infection between adult patients with allogenic and autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. Biol Blood Marrow Transplant. 2013 Jun;19(6):994-9. doi: 10.1016/j.bbmt.2013.03.019. Epub 2013 Apr 6.
2013 Hong J, Kim JY, Ahn HK, Lee SM, Sym SJ, Park J, Cho EK, Ahn JY, Park S, Lee SP, Shin DB, Lee JH. Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma. Support Care Cancer. 2013 Apr;21(4):1145-52. doi: 10.1007/s00520-012-1639-9. Epub 2012 Oct 31.
More